MedTrace Logo

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee

NCT00878501 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2012-06-04

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with osteoarthritis of the knee and at what dose. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.

Conditions

Interventions

DRUG

AZD1386

oral, during 4 weeks

DRUG

AZD1386

oral, during 4 weeks

DRUG

Placebo

Oral, during 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Richard L Leff, MD · AZD1386AstraZeneca R&D Wilmington, USA

  • Ola Svensson, MD · AZD1386AstraZeneca R&D Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Bulgaria
  • Canada
  • Finland
  • Hungary
  • Japan
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878501 on ClinicalTrials.gov